E. Kubista

9.2k total citations · 1 hit paper
247 papers, 6.8k citations indexed

About

E. Kubista is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, E. Kubista has authored 247 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Oncology, 64 papers in Genetics and 56 papers in Cancer Research. Recurrent topics in E. Kubista's work include Estrogen and related hormone effects (49 papers), Breast Cancer Treatment Studies (47 papers) and HER2/EGFR in Cancer Research (39 papers). E. Kubista is often cited by papers focused on Estrogen and related hormone effects (49 papers), Breast Cancer Treatment Studies (47 papers) and HER2/EGFR in Cancer Research (39 papers). E. Kubista collaborates with scholars based in Austria, Germany and United States. E. Kubista's co-authors include K. Czerwenka, R. Jakesz, Christian F. Singer, Gernot Hudelist, Michael Gnant, H. Hausmaninger, Hellmut Samonigg, W. Kwasny, M. Manavi and Michael Seifert and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

E. Kubista

233 papers receiving 6.6k citations

Hit Papers

Phase II Randomized Study of Neoadjuvant Everolimus Plus ... 2009 2026 2014 2020 2009 100 200 300 400 500

Peers

E. Kubista
Comparison fields: 5 of 148
  • Oncology 3.7k
  • Cancer Research 2.4k
  • Molecular Biology 2.0k
  • Genetics 1.6k
  • Pulmonary and Respiratory Medicine 1.1k
Replace P Sismondi with:
P Sismondi Italy
M. Kaufmann Germany
Christian F. Singer Austria
Hellmut Samonigg Austria
Marcella Mottolese Italy
Hans-Jörg Senn Switzerland
Dean B. Evans Switzerland
Robert S. Warren United States
Irene L. Andrulis Canada
Elizabeth Claire Dees United States
P Sismondi Italy View profile →
Citations per field, relative to E. Kubista
E. Kubista · 1×
Citations per year, relative to E. Kubista
E. Kubista · 1×

Countries citing papers authored by E. Kubista

Since Specialization
Citations

This map shows the geographic impact of E. Kubista's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Kubista with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Kubista more than expected).

Fields of papers citing papers by E. Kubista

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Kubista. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Kubista. The network helps show where E. Kubista may publish in the future.

Co-authorship network of co-authors of E. Kubista

This figure shows the co-authorship network connecting the top 25 collaborators of E. Kubista. A scholar is included among the top collaborators of E. Kubista based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Kubista. E. Kubista is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
アジュバント内分泌療法へのゾレドロン酸(ZOL)追加はホルモン応答性早期乳房腫瘍(HREBC)の閉経前女性の無病生存(DF)及び非再発生存(RFS)を改善する:オーストリア乳房腫瘍及び結腸直腸腫瘍研究グループ12(ABCSG-12)試験の多変量解析
1
2 13
3
Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters.
50
4 46
5 23
6 48
7 203
8
Behandlung klimakterischer Symptome nach Brustkrebs mit Liviel(R) - Die LIBERATE-Studie
1
9 77
10
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
332
11 50
12
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
159
13
[Breast cancer: figures and facts].
14
14 4
15 72
16 32
17
Beta-endorphin, steroids, and prolactin. Immunoassay in breast cysts and blood.
3
18 7
19 0
20
[Influence of social status on pregnancy, delivery and puerperium].
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026